Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Global pharma brands: are they worth the effort?

Ed Stapor of Havas Health questions whether global brands are worth the effort and highlights the success factors for achieving top pharma global brands. What do Apple, Coca-Cola, McDonald’s, BMW, HSBC, Nike, Disney, IKEA, Starbucks, and Louis Vuitton have in common? Each has clearly...

Articles

Healthcare markets in Asia: Indian medical device regulatory...

Ames Gross continues his overview of healthcare markets in Asia with an update on the medical device market in India. The medical device market in India was worth an estimated $3.2 billion in 2011, trailing only Japan, China and South Korea in Asia. The medical...

Articles

Emerging diagnostic technologies – the regulatory and reimbu...

Kyle Fetter offers advice on the current regulatory and reimbursement landscape surrounding emerging diagnostic technologies in our latest interview. The fastest growing segment of the laboratory market is molecular diagnostics. The rapid growth of molecular diagnostics as a segment of…

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access